XHANCE uses an Optinose Exhalation Delivery System (EDS) that is designed to deliver medication1,2:

  • High and deep in the nasal passages
  • To regions where nasal polyps originate and sinuses drain and ventilate

XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.

Scroll down to explore reasons to prescribe XHANCE.

About Nasal Polyps

Chronic inflammation associated with nasal polyposis is generally high and deep and difficult to reach

The ostiomeatal complex (OMC) is a region where nasal polyps usually originate and through which most sinuses drain and ventilate.3-6 The complexity of the nasal anatomy makes it difficult to deliver medication into the OMC.3-6

Learn more

Exhalation Delivery Systems

XHANCE is designed to deposit medication high and deep in the nasal passages

XHANCE utilizes an Optinose Exhalation Delivery System (EDS) designed to deliver medication high and deep in the nasal passages, where nasal polyps originate and sinuses drain and ventilate.1-6

Learn more

Clinical Trial Results

Improvement in all 4 defining symptoms and reduction in nasal polyp grade

  • Patients using XHANCE reported improvement in congestion and other defining nasal symptoms1,7
  • XHANCE significantly reduced bilateral polyp grade, with some patients achieving polyp elimination1,7

Learn more

Dosing and Administration

Prescribing and administering XHANCE is simple

  • The recommended dosage for XHANCE is 1 spray per nostril twice daily
  • XHANCE is also approved for 2 sprays per nostril twice daily
  • > 90% of patients in clinical trials considered XHANCE easy to use2

Learn more

  1. Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2017.
  2. Data on file. OptiNose US, Inc.
  3. Zhong C, Jiang Z, Zhang X. Effect of distribution of nasal polyps in ostiomeatal complex on long-term outcomes after endoscopic surgery. Eur Arch Otorhinolaryngol. 2015;272(12):3757-3762.
  4. Larsen PL, Tos M. Origin of nasal polyps: an endoscopic autopsy study. Laryngoscope. 2004;114(4):710-719.
  5. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res. 2013;3(1):42-62.
  6. Liang J, Lane AP. Topical drug delivery for chronic rhinosinusitis. Curr Otorhinolaryngol Rep. 2013;1(1):51-60.
  7. Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: randomized double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis. J Allergy Clin Immunol. 2018; In press.